|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 187,300.00 KRW | +0.11% |
|
+0.81% | +3.89% |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biopharmaceutical | 1,690B | 1,616B | 1,937B | 1,873B | 6,070B | |||||
D&A | 163B | 174B | 175B | 195B | 386B | |||||
Operating Income | 703B | 712B | 618B | 638B | 1,199B | |||||
Pharmaceutical Products | ||||||||||
Chemical Drugs | 242B | 557B | 654B | 501B | 531B | |||||
D&A | 16.49B | 46.13B | 51.1B | 53.81B | 35.52B | |||||
Operating Income | 8.53B | 57.49B | 34.61B | 27.86B | 9.18B | |||||
Other | 2.63B | 3.05B | 3.88B | 5.14B | 5.82B | |||||
D&A | 277M | 281M | 297M | 240M | 256M | |||||
Operating Income | 211M | 224M | 294M | 454M | 506M | |||||
Intersectoral Insider Transaction Reconciliation | -85.76B | -264B | -311B | -203B | -3,050B | |||||
D&A | -328M | -320M | -304M | -3.1B | -4.02B | |||||
Operating Income | 599M | -17.06B | -5.3B | -15.2B | -717B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
South Korea | 1,542B | 2,015B | 2,324B | 2,262B | 4,184B | |||||
Total Assets | - | 2,160B | 2,341B | 14,258B | 10,031B | |||||
Europe | - | - | - | - | 1,862B | |||||
Total Assets | - | - | - | 185B | 779B | |||||
Total Assets | - | - | - | 3.48B | - | |||||
Total Assets | - | - | - | 1.72B | - | |||||
Asia | - | 76.42B | 140B | 117B | 252B | |||||
Total Assets | - | 308B | 300B | 117B | 117B | |||||
North America | - | - | - | - | 168B | |||||
Total Assets | - | - | - | 7.91B | 3,964B | |||||
Total Assets | - | - | - | - | 92.28B | |||||
Central and South America | - | - | - | - | 141B | |||||
Americas | - | 84.61B | 131B | - | - | |||||
Total Assets | - | 209M | - | - | - | |||||
Foreign | 308B | - | - | - | - | |||||
Consolidation Adjustment | - | -264B | -311B | -203B | -3,050B | |||||
Total Assets | - | -5.98B | -11.1B | -22.06B | -36.57B |
- Stock Market
- Equities
- A068270 Stock
- Financials Celltrion, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition